Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML

Evan C Chen,1 Amir T Fathi,2 Andrew M Brunner2 1Department of Medicine, Massachusetts General Hospital, Boston, MA, USA; 2Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA Abstract: Despite increasing understanding of the pathobiology of acute myeloid leukemia (AML...

Full description

Bibliographic Details
Main Authors: Chen EC, Fathi AT, Brunner AM
Format: Article
Language:English
Published: Dove Medical Press 2018-06-01
Series:OncoTargets and Therapy
Subjects:
Acute myeloid leukemia
AML
liposome
liposomal
vyxeos
CPX-351
cytarabine
daunorubicin
Online Access:https://www.dovepress.com/reformulating-acute-myeloid-leukemia-liposomal-cytarabine-and-daunorub-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/reformulating-acute-myeloid-leukemia-liposomal-cytarabine-and-daunorub-peer-reviewed-article-OTT

Similar Items